Efficacy and Safety of Intranasal Glucagon for Treatment of Induced Hypoglycemia in Adults with Diabetes
The purpose of this study is to test the safety and effectiveness of emergency glucagon given as a spray into the nose, when compared with glucagon given by injection.
Type 1 and Type 2 diabetes mellitus
18-64 years old
Diagnosed with type 1 diabetes for at least 2 years and using insulin therapy since diagnosis
Diagnosed with type 2 diabetes and using multiple daily insulin therapy for at least 2 years
BMI that is not too low or too high
Must not be pregnant
Have not experienced a very low blood sugar that required assistance from another person for treatment in the last month
Do not regularly drink 3 or more alcoholic beverages per day
Have not donated blood in the last 2 months
Have not participated in another study within the last month
18 - 64
Healthy Volunteers Needed
Duration of Participation
3 visits to OHSU within 1-3 months. The first visit will last approximately 1.5 hours. Both the 2nd and 3rd visits will last approximately 6 hours.
Contact the OHSU Harold Schnitzer Diabetes Health Center Research Department at (503) 494-4704 or by email at DMResearchCenter@ohsu.edu for more information.
AMG Medical, funded by the Leona M. and Harry B. Helmsley Charitable Trust
All study-related care is provided at no cost to qualified participants including physical examinations. Compensation of up to $500 will be provided.